Cardiovascular toxicities associated with novel cellular immune therapies
Abstract: Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cel...
Saved in:
| Main Authors: | Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
by: John L. Vaughn, et al.
Published: (2025-04-01) -
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
by: Allison M. Bock, et al.
Published: (2025-07-01) -
Solid tumour cellular therapy — principles of toxicity management
by: M. Julve, et al.
Published: (2025-03-01) -
Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy
by: Jia-Hui Liu, et al.
Published: (2025-05-01) -
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2024-11-01)